Suppr超能文献

肝细胞癌患者中诊断延迟很常见。

Diagnostic delays are common among patients with hepatocellular carcinoma.

作者信息

Patel Nishant, Yopp Adam C, Singal Amit G

机构信息

From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas.

From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas.

出版信息

J Natl Compr Canc Netw. 2015 May;13(5):543-9. doi: 10.6004/jnccn.2015.0074.

Abstract

BACKGROUND

Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear.

PURPOSE

To identify and characterize factors associated with diagnostic delays among patients with HCC.

METHODS

Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays.

RESULTS

Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater.

CONCLUSIONS

Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.

摘要

背景

大多数肝细胞癌(HCC)患者就诊时已处于晚期。HCC患者诊断评估过程中延误的发生率及其临床影响尚不清楚。

目的

确定并描述与HCC患者诊断延误相关的因素。

方法

回顾了2005年1月至2012年7月间一家大型城市医院连续收治的肝硬化和HCC患者的记录。采用Kaplan-Meier分析确定从就诊到诊断的时间。诊断延误定义为诊断时间超过3个月,并使用多因素逻辑回归分析来确定诊断延误的相关因素。

结果

在457例HCC患者中,226例(49.5%)为门诊诊断。其中,诊断的中位时间为2.2个月,87例患者(38.5%)经历了诊断延误。诊断延误与肝性脑病的存在呈正相关(比值比[OR],2.29;95%可信区间[CI],1.03 - 5.07),与电子病历(EMR)实施后就诊呈负相关(OR,0.28;95%CI,0.15 - 0.52),在多因素分析中与超声异常就诊也呈负相关(OR,0.36;95%CI,0.19 - 0.67)。肝性脑病患者的诊断延误率较高(56%对35%),而EMR实施后就诊的患者以及超声异常就诊(无论甲胎蛋白水平是否升高)的患者诊断延误率较低(26%对60%以及27%对50%)。在49例有肿块形成的HCC且诊断延误的患者中,18%的患者肿瘤在间隔期生长了2 cm或更大。

结论

近20%的HCC患者从就诊到诊断等待超过3个月,这可能导致肿瘤在间隔期生长。

相似文献

9
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma.肝细胞癌患者的诊断和治疗延误。
J Natl Compr Canc Netw. 2021 May 28;19(9):1063-1071. doi: 10.6004/jnccn.2020.7689.

引用本文的文献

3
Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.人工智能在肝细胞癌诊断中的应用。
eGastroenterology. 2023 Nov 30;1(2):e100002. doi: 10.1136/egastro-2023-100002. eCollection 2023 Sep.
7
Educational Case: Hepatocellular carcinoma.教学病例:肝细胞癌
Acad Pathol. 2024 Feb 26;11(1):100108. doi: 10.1016/j.acpath.2024.100108. eCollection 2024 Jan-Mar.
8
Liquid Liver Biopsy for Disease Diagnosis and Prognosis.用于疾病诊断和预后的液体肝活检
J Clin Transl Hepatol. 2023 Dec 28;11(7):1520-1541. doi: 10.14218/JCTH.2023.00040. Epub 2023 Jul 27.

本文引用的文献

1
Hepatocellular carcinoma tumour markers: current role and expectations.肝细胞癌肿瘤标志物:当前作用与期望
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-53. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22.
4
Screening process failures for hepatocellular carcinoma.肝细胞癌的筛查流程失败。
J Natl Compr Canc Netw. 2014 Mar 1;12(3):375-82. doi: 10.6004/jnccn.2014.0039.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验